Right to Adequate Muscle Mass

“There is probably no decline in structure and function more dramatic than the decline in lean body mass or muscle mass over the decades of life. And yet there is no more common denominator to problems of impaired mobility, altered energy balance, and even loss of vitality than the loss of muscle mass.” — Irwin H. Rosenberg, Journal of Nutrition, 1997

A measurable condition that no ordinary examination measures

Muscle mass is a physiological parameter with normative values by age and sex, with several validated modalities of measurement (dual-energy X-ray absorptiometry, bioelectrical impedance, magnetic resonance imaging, muscle ultrasound, D3-creatine dilution), and with a well-documented cascade of consequences when it falls below a threshold of function. It is, by every technical criterion, a candidate for routine surveillance in the same way that blood pressure, cholesterol, and glycaemia are.

It is not surveyed. In the ordinary encounter with primary care, an adult of forty, fifty, or sixty years does not have their muscle mass measured. The parameter is treated as a late geriatric concern, an object of specialist evaluation once the fall has happened, once the recovery from surgery has been poor, once the chemotherapy has been mistolerated, once frailty has been named clinically. The half-century of degradation that precedes those moments passes unrecorded. When the diagnosis is finally made, the term used is sarcopenia, a word coined by Irwin Rosenberg in 1988 to name a condition that until then had no name, and that even now, four decades later, has no place in the routine physical examination.

The physiological right this page defends is the right of the person concerned to have this parameter measured at ages where the correction is still tractable, named against a threshold of function rather than a threshold of clinical catastrophe, and, where deficient, actually restored to a normative range. The right is not a claim about exercise physiology. It is a claim that the endpoint the profession would recognize and the endpoint the subject lives with should meet.

A century of degradation without a name

The recognition of muscle loss as a distinct clinical entity is remarkably recent. The condition was described in geriatric literature as “wasting” or “involutional atrophy” for most of the twentieth century, without being distinguished from the general decline of ageing. It was named only in 1988–1989, when Irwin H. Rosenberg, then at the USDA Human Nutrition Research Center on Aging at Tufts, coined the term sarcopenia (from Greek sarx, flesh, and penia, loss) and argued that the age-related loss of muscle mass deserved its own diagnostic category. His 1989 summary comments in the American Journal of Clinical Nutrition and his 1997 Journal of Nutrition paper on origins and clinical relevance are the founding texts of the field.

The quantification of the parameter followed. In 1998, Richard N. Baumgartner and colleagues, in American Journal of Epidemiology, proposed the appendicular skeletal muscle mass index (ASMI), derived from DEXA and adjusted for height squared. The New Mexico Aging Process Study that anchored the paper became the reference cohort for the field, and the ASMI thresholds derived from it are still cited in most current definitions.

The operationalization as a clinical diagnosis came later still. In 2010, the European Working Group on Sarcopenia in Older People (EWGSOP), chaired by Alfonso J. Cruz-Jentoft, published in Age and Ageing the first European consensus definition, which required the combination of low muscle mass and low muscle function. In 2019, the same group revised the definition (EWGSOP2), placing muscle strength at the centre of the algorithm and treating muscle mass as the confirmatory rather than the primary criterion. The Asian Working Group for Sarcopenia (AWGS) issued a parallel consensus in 2014 and updated it in 2020, with thresholds calibrated to Asian body morphology. The Sarcopenia Definition and Outcomes Consortium (SDOC), a North American initiative led by Shalender Bhasin and colleagues, published in 2020 in the Journal of the American Geriatrics Society a position statement that anchored diagnosis in low grip strength and low gait speed.

For the specific case of sarcopenic obesity, the wait was longer still. It was only in 2022, in Obesity Facts, that the European Society for Clinical Nutrition and Metabolism (ESPEN) and the European Association for the Study of Obesity (EASO) jointly published a consensus definition of the entity, a full quarter-century after the co-occurrence of low muscle mass and excess adiposity had been described as a phenotype at particularly poor prognosis.

The chronology is instructive. It took thirty years, from Rosenberg’s 1988 naming to the ESPEN/EASO 2022 consensus, to bring the co-occurrence of two of the most common physiological states of the second half of life into a single operational definition. The parameter that spans the whole of adult life has been institutionally attended to as a problem of the very old.

Why the standard examination measures nothing

The measurement exists

Muscle mass can be measured by dual-energy X-ray absorptiometry (DEXA), which is the reference modality in most clinical studies, by bioelectrical impedance analysis (BIA), which is cheap and portable, by magnetic resonance imaging (MRI), which is expensive but discriminating, by peripheral quantitative computed tomography, and, in research settings, by D3-creatine dilution, which measures functional muscle mass rather than lean mass in general. Muscle function is measurable by hand-grip dynamometry, by the timed chair-rise test, by usual gait speed, by the timed up-and-go test, by the Short Physical Performance Battery (SPPB). None of these tools requires specialized training beyond what a primary care nurse can be given in an afternoon.

The measurement is not ordered

In ordinary primary care, no one orders any of them for an adult who is not visibly frail. DEXA is reimbursed in most jurisdictions for the diagnosis of osteoporosis, and its muscle-mass output, which the same scanner produces, is discarded or ignored. BIA is present in most commercial gyms and in almost no clinics. Grip strength is measured routinely in occupational therapy and in geriatric assessment, and almost never in the primary care of a person in their fifties.

The consequence is that the parameter is diagnosed on its worst-case day. A fall, a hip fracture, a poor recovery from abdominal surgery, a chemotherapy-limiting cachexia, a nursing-home admission for loss of autonomy. At that point the diagnosis is made and named, and the trajectory of restoration is at its longest and most uncertain. The three, four, five decades during which the parameter was falling gradually, and during which a modest correction would have been simple, were spent by a medical apparatus that considered the parameter someone else’s concern.

This mirrors, exactly, the pattern documented on this resource for magnesium, potassium, and ferritin. A real physiological parameter has a real test, the test is not ordered, and the parameter enters the clinical record only when its depletion has produced a categorical event. The reference range in the population data that would define a threshold of function is deferred to the categorical events themselves, which pushes the threshold below the level at which restoration is easy and toward the level at which it is heroic.

Muscle as an organ, not merely a mover

The reason the parameter matters at ages long before mobility is threatened is that skeletal muscle is not only a locomotor tissue. It is a metabolic, endocrine, and immune organ whose functional roles are exercised continuously, and whose depletion has consequences well before any perceptible weakness.

The metabolic role

Skeletal muscle is the principal tissue of insulin-mediated glucose uptake, disposing of the greater part of an ingested carbohydrate load in the postprandial hours. It is also the principal contributor to resting energy expenditure, which is why lean mass, not fat mass, is the largest determinant of basal metabolic rate. It is the principal reservoir of free amino acids in states of catabolic stress, fasting, sepsis, surgery, cancer, and its depletion in those states directly predicts recovery. Robert R. Wolfe, in a 2006 paper in American Journal of Clinical Nutrition titled The underappreciated role of muscle in health and disease, laid the foundation for reading muscle as a metabolic buffer whose adequacy is not decorative.

The endocrine role

Since the early 2000s, skeletal muscle has been recognized as an endocrine organ secreting a class of signalling molecules called myokines: interleukin-6, myostatin, irisin, interleukin-15, brain-derived neurotrophic factor, and others. Bente K. Pedersen and Mark A. Febbraio, in Nature Reviews Endocrinology in 2012, in a landmark review titled Muscles, exercise and obesity: skeletal muscle as a secretory organ, showed that these molecules mediate crosstalk between muscle and adipose tissue, liver, brain, bone, and immune system. Their production depends on the amount of contracting tissue available. A depleted muscle bed produces a smaller myokine signal, and the downstream tissues it addresses receive a correspondingly smaller message.

The immune and structural roles

Muscle mass predicts recovery from sepsis and from severe COVID-19. It predicts tolerance of chemotherapy, with sarcopenic cancer patients receiving lower doses, experiencing more toxicity, and surviving less. It is coupled mechanically and hormonally to bone density, and the loss of one accelerates the loss of the other. It provides the mechanical substrate for the joint stabilization that protects against injury. It is, in every measurable sense, a load-bearing structure of health, not a cosmetic detail.

An inventory of associated conditions

The list is long, and it does not depend on frailty being visible. The point of naming these associations is not to imply that muscle deficit is the cause of each condition, which it is not; the point is that in each of them, muscle mass is a modifiable factor whose measurement and correction is currently absent from ordinary care.

The last row deserves an explicit note. The rapid diffusion, since 2022, of GLP-1 receptor agonists as anti-obesity medications has produced total weight loss of a magnitude previously reserved to bariatric surgery, with an unusually high proportion of the lost mass being lean rather than adipose. The endocrinological community that welcomed the therapeutic breakthrough has since begun to publish, notably in Lancet Diabetes and Endocrinology and in Nature Metabolism, on the metabolic disadvantage that follows when the treatment is not paired with a protein-and-resistance-training protocol adequate to preserve the tissue. The concern reproduces the same underlying premise this page defends: that muscle mass is a structural physiological parameter whose adequacy is not incidental.

Muscle mass and all-cause mortality

The most direct evidence of the parameter’s standing as a health-relevant variable is its independent association with all-cause mortality. Preethi Srikanthan and Arun S. Karlamangla, in American Journal of Medicine in 2014, in a paper titled Muscle mass index as a predictor of longevity in older adults, reported that in the NHANES III cohort, higher muscle mass was associated with lower all-cause mortality independently of BMI, waist circumference, and cardiometabolic risk factors. The finding has since been replicated in several other cohorts. It supports the reading that muscle mass is not a marker of general vitality but a distinct predictor of survival.

The sarcopenic obesity case

Sarcopenic obesity is the co-occurrence, in the same subject, of low muscle mass and elevated body fat. It is a phenotype at particularly poor metabolic prognosis, worse than either sarcopenia alone or obesity alone. The 2022 ESPEN/EASO consensus definition operationalized the diagnosis and provided the field with a stable target. What the field has not yet done, in the current state of the literature, is to ask whether an obese subject with a muscle deficit can, under adequate intervention, actually leave the diagnostic category. The critique piece The Strength They Measure, the Mass They Miss documents this specific gap and the one recent trial that has posed the question.

What restores the tissue when it is depleted

The right this page defends is not a right to a specific protocol. It is a right to have the parameter treated with an intervention adequate to the deficit, delivered under conditions that permit its restoration. The literature on restoration converges on a small number of ingredients.

Resistance training at a dose sufficient for hypertrophy. Not a walk, not a group aerobic class, not a functional gym session that leaves the muscle undertaxed. The trials that produce a normalization of muscle mass, when they exist, use a progressive protocol of moderate to high mechanical load, delivered two to three times per week, over months, with continuous progression. The 32-week power-training protocol of Polo-Ferrero and colleagues (2025) is a working template for the sarcopenic obese; the six-month high-intensity protocol of Flor-Rufino and colleagues (2023) is a template for the sarcopenic older adult without obesity. Both produced substantive rates of exit from the diagnostic category.

Protein intake above the current RDA. The current recommended dietary allowance for protein (0.8 g/kg/day in most jurisdictions) was set as the minimum to avoid nitrogen balance loss in a healthy young adult. It is not a target adequate for the older adult, and it is not a target adequate for the subject seeking to rebuild depleted muscle. The PROT-AGE Study Group, in a 2013 position paper in Journal of the American Medical Directors Association, recommended 1.0 to 1.2 g/kg/day for healthy older adults and 1.2 to 1.5 g/kg/day for older adults with acute or chronic illness. The distribution of the intake across the day, with at least 25 to 30 g of high-quality protein per meal, matters as much as the total. The current RDA is the same kind of institutional artefact as the ferritin cutoff of 15 μg/L: a threshold set to avoid a categorical deficiency, mistaken for a threshold of adequacy.

Leucine and essential amino acids. The anabolic response to a meal is triggered largely by leucine, an essential amino acid whose intracellular concentration activates the mTOR pathway. Older adults show anabolic resistance, a blunted response to a given protein dose, which is one of the reasons the older adult’s protein requirement is higher than the young adult’s. Whey protein, which is leucine-rich and rapidly digested, is one of the tools that address this specifically.

Creatine. Long framed as a supplement for competitive athletes, creatine monohydrate has an evidence base for muscle mass and strength that extends squarely into the older adult population. The International Society of Sports Nutrition position stand of 2017 and subsequent literature support its use at 3 to 5 g per day, in the ordinary generic monohydrate form. The physiological logic is the same as for the other substrates documented on this resource: a naturally occurring molecule, produced endogenously in insufficient quantity for the ambition of restoration, safely supplementable at generic cost.

Vitamin D and testosterone where deficient. Both are permissive factors for muscle protein synthesis and for the anabolic response to training. Correcting a documented deficit is part of the intervention; substituting for the absence of it is not.

Sleep, and the absence of chronic inflammation. Muscle protein synthesis is a nocturnal process. Chronic inflammation, chronic stress, poor sleep are all conditions that shift the tissue toward catabolism. The restorative intervention has to be delivered into a body that is metabolically permitting it.

Experts, in their own words

Irwin H. Rosenberg — the founder

Rosenberg’s 1997 Journal of Nutrition paper on the origins and clinical relevance of sarcopenia contains the sentence that has been the epigraph of the field ever since:

“There is probably no decline in structure and function more dramatic than the decline in lean body mass or muscle mass over the decades of life. And yet there is no more common denominator to problems of impaired mobility, altered energy balance, and even loss of vitality than the loss of muscle mass.”

He had already introduced the term nine years earlier at a conference on Health and Aging, and had allowed it to be published in the American Journal of Clinical Nutrition proceedings in 1989. Almost forty years later, the term has entered international consensus, and the routine physical examination has not.

Alfonso J. Cruz-Jentoft — the operationalizer

Chair of the European Working Group on Sarcopenia in Older People through both the 2010 and 2019 consensus statements, Cruz-Jentoft is the person most responsible for turning Rosenberg’s naming into a clinical instrument. His 2019 revision (Age and Ageing, 48:16-31) placed low muscle strength at the front of the diagnostic algorithm, treating low muscle mass as confirmatory, on the pragmatic reasoning that grip strength can be measured everywhere and DEXA cannot. The choice is defensible operationally and reveals the underlying constraint: the diagnostic algorithm is calibrated to what routine care will actually measure, not to what the physiology would call for.

Richard N. Baumgartner — the metrician

Baumgartner’s 1998 American Journal of Epidemiology paper on the epidemiology of sarcopenia in New Mexico produced the appendicular skeletal muscle mass index (ASMI) and the population-based cutoffs that anchored the field for two decades. His work is the reason the current diagnostic algorithms have numerical thresholds at all.

Robert R. Wolfe — the metabolist

Wolfe’s 2006 paper in American Journal of Clinical Nutrition, The underappreciated role of muscle in health and disease, is the argumentative core of the case for muscle as a metabolic and not merely a locomotor organ. His subsequent work at the University of Arkansas for Medical Sciences on protein turnover, on the amino acid response to feeding, and on the pathophysiology of anabolic resistance in ageing has provided the mechanistic foundation for the protein-intake recommendations that the geriatric nutrition community has been building since.

William J. Evans, Roger A. Fielding, Anne B. Newman — the field-builders

Evans (Berkeley and Duke), Fielding (Tufts), and Newman (Pittsburgh) are three of the researchers who translated Rosenberg’s concept into a clinical field over the following three decades, through the Health ABC cohort, the LIFE trial (Fielding as PI), and the successive editions of geriatric nutrition guidelines. Their combined bibliography is one of the pillars on which any serious contemporary muscle-mass literature rests.

Health policies facing their own gap

The parameter absent from public health

No national public health framework treats muscle mass as an explicit objective of population surveillance. Body mass index, blood pressure, cholesterol, glycaemia are the four parameters that appear in every screening protocol, in every occupational health check, in every insurance underwriting form. Muscle mass appears nowhere. The comparison is instructive because muscle mass has, on any credible reading of the evidence, a comparable predictive strength for mortality and for autonomy.

The categorical exclusion of the middle years

The screening apparatus that does exist for muscle mass is confined to the very old. Geriatric assessment includes it. Occupational therapy assessment includes it. Nothing in the preventive medicine of adults between 30 and 65 years does. The years during which the parameter is most modifiable, and during which a modest and sustained intervention would prevent the trajectory that later becomes categorical, are exactly the years during which no institution is asking.

The reimbursement architecture

DEXA is reimbursed for osteoporosis in most jurisdictions, and the same scan that produces the bone-density output produces the body-composition output. The muscle-mass reading is technically free at the point of measurement, and clinically unused. This is not a matter of cost. It is a matter of what the standard of care asks the modality to look at.

The right invoked here

Under the physiological-rights framework this resource defends, the right to adequate muscle mass is the right of the person concerned to have this parameter measured at ages where correction is tractable, named against a threshold of function rather than a threshold of clinical catastrophe, and, where deficient, actually restored to a normative range under an intervention adequate to the deficit. The instruments already exist to support the claim. The right to health under Article 12 of the International Covenant on Economic, Social and Cultural Rights, read through General Comment 14 of the Committee on Economic, Social and Cultural Rights, obliges the state to provide the conditions under which physiological adequacy is attainable. The self-care doctrine articulated in the Alma-Ata Declaration and in the WHO Self-Care Interventions programme protects the subject who acts on their own body when the standard of care declines to do so. The vocabulary under which this right is currently unarticulated is the missing element, and the argument this resource is building is that its articulation is a matter of naming rather than of doctrine.

Continuity with Jean Mayer, 1979

The doctrinal root of the physiological-rights framework this resource defends is Jean Mayer’s 1979 address to the Société française de nutrition, titled Les droits physiologiques de l’homme. In that address, Mayer described the decline of physical activity in industrial societies as a major physiological phenomenon whose medical consequences were being underestimated and neglected. His research at Harvard on the regulation of appetite by physical activity had shown that below a certain level of activity, the food-intake regulation that normally matches appetite to expenditure with an accuracy of a fraction of a percent ceases to function accurately, and the caloric intake fixes at a level that produces obesity.

The claim of the present page is, in one sense, the extension of Mayer’s argument to the parameter that Mayer’s line of research anticipated but did not name in the same terms. The physiological substrate that carries the burden of the metabolic disadvantage he described is muscle. The right to adequate physical activity, which was Mayer’s formulation, is inseparable from the right to the mass of tissue that physical activity depends on and produces. The page you are reading is the tissue-level formulation of the parameter he identified in 1979 at the level of behaviour.

Timeline: from unnamed decline to unfilled right

References

1. Rosenberg IH. Summary comments. American Journal of Clinical Nutrition. 1989;50:1231-1233. (First published use of the term sarcopenia.)
2. Rosenberg IH. Sarcopenia: origins and clinical relevance. Journal of Nutrition. 1997;127(5 Suppl):990S-991S. PubMed 9164280
3. Baumgartner RN, Koehler KM, Gallagher D, Romero L, Heymsfield SB, Ross RR, Garry PJ, Lindeman RD. Epidemiology of sarcopenia among the elderly in New Mexico. American Journal of Epidemiology. 1998;147(8):755-763. PubMed 9554417
4. Wolfe RR. The underappreciated role of muscle in health and disease. American Journal of Clinical Nutrition. 2006;84(3):475-482. PubMed 16960159
5. Cruz-Jentoft AJ, Baeyens JP, Bauer JM, et al. Sarcopenia: European consensus on definition and diagnosis. Report of the European Working Group on Sarcopenia in Older People. Age and Ageing. 2010;39(4):412-423. PubMed 20392703
6. Pedersen BK, Febbraio MA. Muscles, exercise and obesity: skeletal muscle as a secretory organ. Nature Reviews Endocrinology. 2012;8(8):457-465. PubMed 22473333
7. Bauer J, Biolo G, Cederholm T, et al. Evidence-based recommendations for optimal dietary protein intake in older people: a position paper from the PROT-AGE Study Group. Journal of the American Medical Directors Association. 2013;14(8):542-559. PubMed 23867520
8. Srikanthan P, Karlamangla AS. Muscle mass index as a predictor of longevity in older adults. American Journal of Medicine. 2014;127(6):547-553. PubMed 24561114
9. Kreider RB, Kalman DS, Antonio J, et al. International Society of Sports Nutrition position stand: safety and efficacy of creatine supplementation in exercise, sport, and medicine. Journal of the International Society of Sports Nutrition. 2017;14:18. PubMed 28615996
10. Cruz-Jentoft AJ, Bahat G, Bauer J, et al. Sarcopenia: revised European consensus on definition and diagnosis. Age and Ageing. 2019;48(1):16-31. PubMed 30312372
11. Bhasin S, Travison TG, Manini TM, et al. Sarcopenia Definition: The Position Statements of the Sarcopenia Definition and Outcomes Consortium. Journal of the American Geriatrics Society. 2020;68(7):1410-1418. PubMed 32150289
12. Chen LK, Woo J, Assantachai P, et al. Asian Working Group for Sarcopenia: 2019 Consensus Update on Sarcopenia Diagnosis and Treatment. Journal of the American Medical Directors Association. 2020;21(3):300-307.e2. PubMed 32033882
13. Donini LM, Busetto L, Bischoff SC, et al. Definition and Diagnostic Criteria for Sarcopenic Obesity: ESPEN and EASO Consensus Statement. Obesity Facts. 2022;15(3):321-335. PubMed 35196654
14. Polo-Ferrero L, Martin MJ, Puente-González AS, Barbero-Iglesias FJ, González-Manzano S, Méndez-Sánchez R. Efficacy of Power Training on Sarcopenic Obesity in Community-Dwelling Older Women: A 32-Week Randomized Clinical Trial. Nutrients. 2025. PubMed 40507091
15. Ma X, Sun G, Liu C, Yan X, Liang W, Ma Z. Exercise-based interventions for sarcopenic obesity in middle-aged and older adults: an umbrella review of systematic reviews with pairwise meta-analyses and network meta-analyses. Frontiers in Nutrition. 2026. doi:10.3389/fnut.2026.1859967
16. Mayer J. Les droits physiologiques de l’homme. Address to the Société française de nutrition, 1979. Republished in this resource: Physiologie et condition humaine — J. Mayer (1979)